CoChat
Sign Up
Cited by 243Carcinogens and Genotoxicity AssessmentContact Dermatitis and AllergiesDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 419 of the 419 references it cites were found in a registry or an index.

Final Report on the Safety Assessment of BHT

Rebecca S Lanigan, Torill A Yamarik·2002·International Journal of Toxicology
DOI 10.1080/10915810290096513
Open this paper in CoChat — free account

Abstract

BHT is the recognized name in the cosmetics industry for butylated hydroxytoluene. BHT is used in a wide range of cosmetic formulations as an antioxidant at concentrations from 0.0002% to 0.5%. BHT does penetrate the skin, but the relatively low amount absorbed remains primarily in the skin. Oral studies demonstrate that BHT is metabolized. The major metabolites appear as the carboxylic acid of BHT and its glucuronide in urine. At acute doses of 0.5 to 1.0 g/kg, some renal and hepatic damage was seen in male rats. Short-term repeated exposure to comparable doses produced hepatic toxic effects in male and female rats. Subchronic feeding and intraperitoneal studies in rats with BHT at lower doses produced increased liver weight, and decreased activity of several hepatic enzymes. In addition to liver and kidney effects, BHT applied to the skin was associated with toxic effects in lung tissue. BHT was not a reproductive or developmental toxin in animals. BHT has been found to enhance and to inhibit the humoral immune response in animals. BHT itself was not generally considered genotoxic, although it did modify the genotoxicity of other agents. BHT has been associated with hepatocellular and pulmonary adenomas in animals, but was not considered carcinogenic and actually was associated with a decreased incidence of neoplasms. BHT has been shown to have tumor promotion effects, to be anticarcinogenic, and to have no effect on other carcinogenic agents, depending on the target organ, exposure parameters, the carcinogen, and the animal tested. Various mechanism studies suggested that BHT toxicity is related to an electrophillic metabolite. In a predictive clinical test, 100% BHT was a mild irritant and a moderate sensitizer. In provocative skin tests, BHT (in the 1% to 2% concentration range) produced positive reactions in a small number of patients. Clinical testing did not find any depigmentation associated with dermal exposure to BHT, although a few case reports of depigmentation were found. The Cosmetic Ingredient Review Expert Panel recognized that oral exposure to BHT was associated with toxic effects in some studies and was negative in others. BHT applied to the skin, however, appears to remain in the skin or pass through only slowly and does not produce systemic exposures to BHT or its metabolites seen with oral exposures. Although there were only limited studies that evaluated the effect of BHT on the skin, the available studies, along with the case literature, demonstrate no significant irritation, sensitization, or photosensitization. Recognizing the low concentration at which this ingredient is currently used in cosmetic formulations, it was concluded that BHT is safe as used in cosmetic formulations.

Overview

Integrity signals

Registry

Crossref · 10.1080/10915810290096513

Cites

419 of 419 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 417 references

Research works printed but not linked: 124

  1. 1977, Lab. Invest., 36, 26
  2. 1975, Dokl. Biol. Sci., 220, 31
  3. Applewhite, T. H., ed. 1985. Bailey's industrial oil and fat products, Vol. 3. 4th ed., 99–100. New York: John Wiley & Sons.
  4. 1992, Anticancer Res., 12, 933
  5. 1978, Res. Commun. Chem. Pathol. Pharmacol., 20, 101
  6. 1988, Photochem. Photobiol., 47, 88S
  7. 1978, Cancer Res., 38, 1384
  8. 1992, Toxicologist, 12, 328
  9. 1991, Drug Metab. Dispos., 19, 467
  10. 1980, Food Technol. Aust., 32, 608
  11. 1990, J. Toxicol. Cut. Ocul. Toxicol., 8, 453
  12. Brown, D. L., S. Endean, S. Bodmer, and C. Cerveny. 1981. Effects of antioxidants on mutagenicity of benzo(a)pyrene and 7,12-dimethylbenzanthracene. In Abstract of the Annual Meeting of the American Society of Microbiologist, Vol. 81, 130.
  13. 1981, Cancer Res., 41, 4938
  14. 1996, Arch. Med. Res., 27, 71
  15. 1982, Cancer Res., 42, 2609
  16. 1993, Mol. Endocrinol., 7, 1596
  17. 1979, J. Natl. Cancer Inst., 63, 1081
  18. 1986, Br. J. Dermatol., 115, 49
  19. 1970, Genetics, 64, s14
  20. 1985, Cancer Chemother. Pharmacol., 14, 243
  21. 1993, Hum. Exp. Toxicol., 12, 560
  22. 1989, Med. Sci. Res., 17, 999
  23. 1973, Ann. Nutr. Aliment., 27, 11
  24. 1996, WHO Food Additives Series, 35, 3
  25. 1996, WHO Food Additives Series, 21, 25
  26. 1983, Dev. Toxicol. Environ. Sci., 11, 475
  27. 1994, Cutis, 53, 232
  28. 1973, Ann. Allergy, 31, 126
  29. 1984, FDA database
  30. 1998, FDA database
  31. 1977, Annu. Rep. Tokyo Metr. Res. Lab., 28, 53
  32. 1981, Agric. Biol. Chem., 45, 1061
  33. 1987, Cancer Res., 47, 2113
  34. 1987, Jpn. J. Cancer Res. (Gann), 78, 689
  35. 1985, J. Toxicol. Sci., 10, 259
  36. 1991, Methods Find. Exp. Clin. Pharmacol., 13, 599
  37. 1981, Cancer Res., 41, 3392
  38. 1984, Clinical toxicology of commercial products
  39. Grant, J., ed. 1972. Hackh's chemical dictionary, 4th ed., 118. New York: McGraw-Hill.
  40. 1996, Cancer Res., 56, 3480
  41. 1993, Teratology, 48, 507
  42. 1989, Sci. Rep. Res. Inst. Tohoku Univ., 36, 1
  43. 1997, HSDB database
  44. 1987, Eur. J. Cancer Clin. Oncol., 23, 1760
  45. 1990, Toxicologist, 10, 297
  46. 1987, Jpn. J. Cancer Res. (Gann), 78, 317
  47. 1986, J. Natl. Cancer Inst., 76, 143
  48. 1987, Drugs Exp. Clin. Res., 13, 577
  49. 1992, Pharm. Acta Helv., 67, 152
  50. 1984, IARC Sci. Publ., 56, 399
  51. 1974, Dros. Info. Serv., 51, 133
  52. 1980, J. Soc. Cosmet. Chem., 31, 1
  53. 1973, Int. J. Radiat. Biol., 23, 295
  54. 1977, Nucleus, 20, 161
  55. 1980, The predictive value of short-term screening tests in carcinogenicity evaluation, 253
  56. 1966, Clin. Res., 14, 299
  57. 1980, Acta Biol. Med. Germ., 39, 717
  58. 1979, Int. J. Vit. Nutr. Res., 49, 352
  59. 1991, Artery, 18, 115
  60. 1967, Lab. Invest., 16, 342
  61. 1994, Cancer Res., 54, 1895s
  62. 1984, Cancer Res., 44, 1604
  63. 1983, Proc. West. Pharmacol. Soc., 26, 417
  64. 1983, J. Natl. Cancer Inst., 70, 931
  65. 1984, J. Natl. Cancer Inst., 73, 925
  66. 1985, Cancer Res., 45, 5751
  67. 1997, Cancer Res., 57, 2832
  68. 1986, Cancer Res., 46, 1694
  69. 1952, Am. Med. Assoc. Arch. Ind. Hyg. Occup. Med., 5, 311
  70. 1985, Dev. Biol. Stand., 60, 371
  71. 1980, Int. J. Radiat. Biol., 38, 559
  72. 1986, Cancer Res., 46, 5264
  73. 1986, Cancer Res., 46, 3907
  74. 1979, J. Natl. Cancer Inst., 63, 473
  75. 1982, Ann. Dermatol. Venereol., 109, 1017
  76. 1987, J. Natl. Cancer Inst., 79, 281
  77. 1986, Toxicol. Lett., 343, 99
  78. 1985, Res. Commun. Chem. Pathol. Pharmacol., 50, 125
  79. 1986, Environ. Mutagen, 8, 1
  80. 1994, Bull. Environ. Contam. Toxicol., 52, 511
  81. 1990, CTFA compendium of cosmetic ingredient composition—specifications
  82. 1970, Arch. Sci. Physiol., 24, 37
  83. 1975, Neoplasma, 22, 251
  84. 1985, Cancer Res., 45, 558
  85. 1988, Human Toxicol., 7, 70
  86. 1974, Int. J. Radiat. Biol., 25, 67
  87. 1997, RTECS database
  88. 1981, Exp. Cell Biol., 49, 294
  89. 1995, Biochem. Mol. Biol. Int., 35, 87
  90. 1977, Can. J. Comp. Med., 41, 195
  91. 1985, J. Toxicol. Sci., 10, 259
  92. 1974, Proc. Int. Symp. Trace Elem. Metab. Anim., 2, 593
  93. 1974, Jpn. J. Pharmacol., 24, 38
  94. 1990, Int. J. Exp. Pathol., 71, 809
  95. 1992, Food Chem. Toxicol., 20, 455
  96. 1977, Cancer Res., 37, 1631
  97. 1984, Am. Rev. Respir. Dis., 130, 895
  98. 1987, Anat. Rec., 218, 218
  99. Subba Rao, V. S., and A. S. Aiyar. 1975. Mutagenicity evaluation studies with food additives and radiolytic products of sugars. Proc. Symp. Mutag. Carcinog. Teratog. Chem. 104–114.
  100. 1989, J. Clin. Electron Microsc., 22, 5
  101. Swern, D., ed. 1982. Bailey's industrial oil and fat products, Vol. 2. 4th ed., 326, 509. New York: John Wiley & Sons.
  102. 1988, Res. Commun. Chem. Pathol. Pharmacol., 61, 291
  103. 1984, J. Pharm. Dyn., 7, s-89
  104. 1981, Gann., 72, 104
  105. 1995, Ind. J. Exp. Biol., 33, 796
  106. 1969, Ind. J. Exp. Biol., 17, 713
  107. Taylor, E. J., ed. 1988. Dorland's illustrated medical dictionary, 27th ed., 1019. Philadelphia, PA: WB Saunders.
  108. 1992, Chem. Biol. Interact., 86, 129
  109. 1990, Adv. Exp. Med. Biol., 283, 393
  110. 1987, Drug Metab. Dispos., 5, 833
  111. 1989, Acta Derm. Venereol. (Stockh.), 69, 12
  112. 1974, Res. Commun. Chem. Pathol. Pharmacol., 8, 289
  113. 1993, J. Pharmacol. Exp. Ther., 266, 958
  114. 1972, J. Natl. Cancer Inst., 48, 1425
  115. 1980, Carcinog. Compr. Surv., 5, 85
  116. Wenninger, J. A., and G. N. McEwen, Jr., eds. 1997. International cosmetic ingredient dictionary and handbook, Vol. 1, 136. Washington, DC: CTFA.
  117. 1978, Drug Metab. Dispos., 6, 296
  118. 1984, Toxicologist, 4, 104
  119. 1991, Cancer Res., 51, 6224
  120. 1980, Am. J. Vet. Res., 41, 391
  121. 1986, Cancer Res., 46, 2675
  122. 1983, J. Natl. Cancer Inst., 71, 859
  123. 1983, Drug Nutr. Interact., 2, 57
  124. 1988, Res. Commun. Chem. Pathol. Pharmacol., 59, 219

Cited by

Sorted by citations

Items 101–200 of 243

Related

See all

Metadata

Authors
Lanigan, R. S., & Yamarik, T. A.
Venue
International Journal of Toxicology
Publisher
SAGE Publications
Published
2002-10
Volume
21
Issue
2_suppl
Pages
19-94
ISSN
  • 1091-5818 (ISSN-L)
  • 1092-874X
DOI
10.1080/10915810290096513
OpenAlex
W2254762588
Cited by
243
References
417
Citations by year
2026: 7 · 2025: 23 · 2024: 20 · 2023: 12 · 2022: 19 · 2021: 28 · 2020: 29 · 2019: 21 · 2018: 20 · 2017: 7 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 9
FWCI
0.40
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • International Journal of Toxicology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
butylated hydroxytoluene, percutaneous absorption, hepatotoxicity, nephrotoxicity, pulmonary toxicity, genotoxicity, tumor promotion, carcinogenicity, skin irritation, skin sensitization, photosensitization, depigmentation, electrophilic metabolites, glucuronide metabolites, reproductive toxicity, immune response
MeSH terms
Animals, Antioxidants, Butylated Hydroxytoluene, Clinical Trials as Topic, Consumer Product Safety, Cosmetics, Dose-Response Relationship, Drug, Drug Administration Routes, Humans, Toxicity Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review